CIK 0001682852
- Large accelerated filer
Moderna, Inc.
Sign in to watch- Ticker
- MRNA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813467528
- Phone
- +1 617-714-6500
- Business address
- 325 BINNEY STREET, CAMBRIDGE, MA, 02142
- Former names
- Moderna Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $50,775,837
- in 5 filings, $50.8M under 10b5-1 plans
Net −$50,775,837. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-05 | AFEYAN NOUBAR Director | Sale 10b5-1 | −400 | $153.71 | $61K | 1,948,652 |
| 2024-06-05 | AFEYAN NOUBAR Director | Sale 10b5-1 | −1,721 | $154.86 | $267K | 1,946,931 |
| 2024-06-03 | Mock James M Chief Financial Officer | Sale 10b5-1 | −691 | $140.72 | $97K | 6,506 |
| 2024-06-03 | Hoge Stephen President | Sale 10b5-1 | −339 | $140.72 | $48K | 1,472,089 |
| 2024-06-03 | Klinger Shannon Thyme Chief Legal Officer | Sale 10b5-1 | −122 | $140.72 | $17K | 10,878 |
| 2024-05-31 | Mock James M Chief Financial Officer | Exercise or conversion 10b5-1 | +1,326 | 7,197 | ||
| 2024-05-31 | Mock James M Chief Financial Officer | Grant or award · Performance Stock Units 10b5-1 | +5,304 | 5,304 | ||
| 2024-05-31 | Mock James M Chief Financial Officer | Exercise or conversion · Performance Stock Units 10b5-1 | −1,326 | 3,978 | ||
| 2024-05-31 | Hoge Stephen President | Exercise or conversion 10b5-1 | +651 | 1,472,428 | ||
| 2024-05-31 | Hoge Stephen President | Exercise or conversion · Restricted Stock Units 10b5-1 | −651 | 4,562 | ||
| 2024-05-31 | Klinger Shannon Thyme Chief Legal Officer | Exercise or conversion 10b5-1 | +232 | 11,000 | ||
| 2024-05-31 | Klinger Shannon Thyme Chief Legal Officer | Exercise or conversion · Restricted Stock Units 10b5-1 | −232 | 1,629 | ||
| 2024-05-29 | AFEYAN NOUBAR Director | Sale 10b5-1 | −1,000 | $141.01 | $141K | 1,980,931 |
| 2024-05-29 | AFEYAN NOUBAR Director | Sale 10b5-1 | −3,013 | $141.73 | $427K | 1,977,918 |
| 2024-05-29 | AFEYAN NOUBAR Director | Sale 10b5-1 | −1,100 | $142.82 | $157K | 1,976,818 |
| 2024-05-29 | AFEYAN NOUBAR Director | Sale 10b5-1 | −1,500 | $143.94 | $216K | 1,975,318 |
| 2024-05-29 | AFEYAN NOUBAR Director | Sale 10b5-1 | −2,400 | $144.99 | $348K | 1,972,918 |
| 2024-05-29 | AFEYAN NOUBAR Director | Sale 10b5-1 | −5,581 | $146.02 | $815K | 1,967,337 |
| 2024-05-29 | AFEYAN NOUBAR Director | Sale 10b5-1 | −2,229 | $146.82 | $327K | 1,965,108 |
| 2024-05-29 | AFEYAN NOUBAR Director | Sale 10b5-1 | −3,177 | $148.06 | $470K | 1,961,931 |
Page 28 of 38 · 743 trades